News
![Median Technologies to Speak at the Radiological Society of North America (RSNA) 2022 Annual Meeting, Nov. 27 - Dec 1, Chicago, IL, USA, With Three Presentations: https://mms.businesswire.com/media/20200113005579/en/767035/5/Median_strapline.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd3BRSFE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6f39fecf5146be08cb4f343c975d6fff3d55bd8d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Median_strapline.jpg?locale=us)
Median Technologies to Speak at the Radiological Society of North America (RSNA) 2022 Annual Meeting, Nov. 27 - Dec 1, Chicago, IL, USA, With Three Presentations
Regulatory News:
Median Technologies (ALMDT) (Paris:ALMDT) announced today that the Company will be speaking and presenting at the world’s largest medical imaging conference, the 2022
![Pharnext: completion of the reverse split of its shares on the basis of 1 new share for 5,000 old shares, start of trading of the shares resulting from the reverse split, and capital reductions](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Pharnext: completion of the reverse split of its shares on the basis of 1 new share for 5,000 old shares, start of trading of the shares resulting from the reverse split, and capital reductions
![CONDOR TECHNOLOGIES KÜNDIGT VORSCHLAG AN: https://mms.businesswire.com/media/20220822005263/en/1549500/5/6BB4D3E2-F9E8-4B4B-A919-BACC3F99E5C0_4_5005_c.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeFArV0E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2da7e5bf957891e25309b3dd67bbda1722bcb9e8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/6BB4D3E2-F9E8-4B4B-A919-BACC3F99E5C0_4_5005_c.jpg?locale=us)
CONDOR TECHNOLOGIES KÜNDIGT VORSCHLAG AN
Condor Technologies NV (EURONEXT: MLMFI ISIN: BE6252013725), gibt bekannt, dass der Vorstand am November 18, 2022 beschlossen hat der Hauptversammlung vorzuschlagen, die Aktien der Condor
![Condor Technologies Announces Proposal: https://mms.businesswire.com/media/20220822005263/en/1549500/5/6BB4D3E2-F9E8-4B4B-A919-BACC3F99E5C0_4_5005_c.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeFArV0E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2da7e5bf957891e25309b3dd67bbda1722bcb9e8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/6BB4D3E2-F9E8-4B4B-A919-BACC3F99E5C0_4_5005_c.jpg?locale=us)
Condor Technologies Announces Proposal
Condor Technologies NV (EURONEXT: MLMFI ISIN: BE6252013725), announces that, on November 18 th.2022, its board of directors has decided to propose to the general shareholders’ meeting to split the
![Valbiotis lanciert Kapitaleinwerbung von rund 8 Mio. Euro zur Beschleunigung seiner Marketingstrategie: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXFzSVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--15bfdf03f8ab493929a3d2392e314697d3469f59/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/valbiotis-logo.jpg?locale=us)
Valbiotis lanciert Kapitaleinwerbung von rund 8 Mio. Euro zur Beschleunigung seiner Marketingstrategie
Valbiotis (FR0013254851 – ALVAL, PEA/KMU-berechtigt) (Paris:ALVAL), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und Bekämpfung von
![BILENDI: Revenues for the 3rd quarter of 2022: +41.9%](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
BILENDI: Revenues for the 3rd quarter of 2022: +41.9%
![Valbiotis schließt Finanzierungsrunde über 9,7 Millionen Euro erfolgreich ab: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXFzSVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--15bfdf03f8ab493929a3d2392e314697d3469f59/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/valbiotis-logo.jpg?locale=us)
Valbiotis schließt Finanzierungsrunde über 9,7 Millionen Euro erfolgreich ab
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, qualifiziert für PEA/SME), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und
![Valbiotis Successfully Completes a Fundraise of 9.7 Million Euros: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXFzSVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--15bfdf03f8ab493929a3d2392e314697d3469f59/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/valbiotis-logo.jpg?locale=us)
Valbiotis Successfully Completes a Fundraise of 9.7 Million Euros
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
![Hugo Brugière Joins Pharnext Board of Directors](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Hugo Brugière Joins Pharnext Board of Directors
![ROCTOOL: Record attendance for Roctool at K-2022 in Germany](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
ROCTOOL: Record attendance for Roctool at K-2022 in Germany
![Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0dxVmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--df3db62501cd2dac51e6a4832a420790d1de65b6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo-sensorion2.jpg?locale=us)
Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing
![Pharnext announces that Neovacs has set-up a management trust to manage the Pharnext securities issued and the rights and obligations of Neovacs under the financing agreement signed on September 30th,](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Pharnext announces that Neovacs has set-up a management trust to manage the Pharnext securities issued and the rights and obligations of Neovacs under the financing agreement signed on September 30th,
![Valbiotis präsentiert auf der Jahrestagung der American Association for the Study of Liver Diseases (AASLD) signifikante präklinische Ergebnisse für seinen Wirkstoff TOTUM•448 gegen Fettlebererkrankungen (NAFL und NASH): https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXFzSVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--15bfdf03f8ab493929a3d2392e314697d3469f59/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/valbiotis-logo.jpg?locale=us)
Valbiotis präsentiert auf der Jahrestagung der American Association for the Study of Liver Diseases (AASLD) signifikante präklinische Ergebnisse für seinen Wirkstoff TOTUM•448 gegen Fettlebererkrankungen (NAFL und NASH)
Regulatorische Nachrichten:
Valbiotis (FR0013254851 – ALVAL, qualifiziert für PEA/SME), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und
![Valbiotis Will Present Significant Preclinical Results for Its Active Substance TOTUM•448 Against Fatty Liver Diseases (NAFL and NASH), at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXFzSVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--15bfdf03f8ab493929a3d2392e314697d3469f59/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/valbiotis-logo.jpg?locale=us)
Valbiotis Will Present Significant Preclinical Results for Its Active Substance TOTUM•448 Against Fatty Liver Diseases (NAFL and NASH), at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
![BIOCORP und NOVO NORDISK verstärken ihre Partnerschaft mit einer neuen Vereinbarung über den Mallya® Smart Sensor: https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNVAxRmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--27e0b79ca4263b2c37c92a647381d83a6cd1d5c8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Logo_Biocorp.jpg?locale=us)
BIOCORP und NOVO NORDISK verstärken ihre Partnerschaft mit einer neuen Vereinbarung über den Mallya® Smart Sensor
BIOCORP (FR0012788065 - ALCOR / Eligible PEA-PME) (Paris:ALCOR), ein französisches Unternehmen, das auf das Design, die Entwicklung und die Herstellung innovativer medizinischer Geräte
![BIOCORP and NOVO NORDISK Strengthen Their Partnership With a New Agreement on Mallya® Smart Sensor: https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNVAxRmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--27e0b79ca4263b2c37c92a647381d83a6cd1d5c8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Logo_Biocorp.jpg?locale=us)
BIOCORP and NOVO NORDISK Strengthen Their Partnership With a New Agreement on Mallya® Smart Sensor
Regulatory News:
BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR), a French company specialized in the design, development, and manufacturing of innovative medical devices
![Sensorion Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0dxVmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--df3db62501cd2dac51e6a4832a420790d1de65b6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo-sensorion2.jpg?locale=us)
Sensorion Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France
Regulatory News:
Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
![Median Technologies Announces Its 2022 Half-year Results and Revenues for the Third Quarter: https://mms.businesswire.com/media/20200113005579/en/767035/5/Median_strapline.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd3BRSFE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6f39fecf5146be08cb4f343c975d6fff3d55bd8d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Median_strapline.jpg?locale=us)
Median Technologies Announces Its 2022 Half-year Results and Revenues for the Third Quarter
Regulatory News:
Median Technologies (Euronext Growth - ALMDT) (Paris:ALMDT), whose Board of Directors approved on October 18, 2022 the consolidated IFRS financial statements for the first half
![ROCTOOL presents its Eco-Molding initiative at K-2022 with 2 live demonstrations](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
ROCTOOL presents its Eco-Molding initiative at K-2022 with 2 live demonstrations
![BD und BIOCORP unterzeichnen Vertrag, um Konnektivität und Rückverfolgbarkeit für selbst verabreichte Injektionspräparate zu schaffen: https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNVAxRmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--27e0b79ca4263b2c37c92a647381d83a6cd1d5c8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Logo_Biocorp.jpg?locale=us)
BD und BIOCORP unterzeichnen Vertrag, um Konnektivität und Rückverfolgbarkeit für selbst verabreichte Injektionspräparate zu schaffen
Regulatorische Nachrichten:
BD (Becton, Dickinson and Company) (NYSE: BDX), ein Weltmarktführer in der Medizintechnik, und Biocorp (Paris:ALCOR), ein in Frankreich ansässiger Hersteller von
![BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs: https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNVAxRmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--27e0b79ca4263b2c37c92a647381d83a6cd1d5c8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Logo_Biocorp.jpg?locale=us)
BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs
Regulatory News:
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biocorp (Paris:ALCOR), a medical device and delivery systems manufacturer based
![Pharnext Reports First Half 2022 Financial Results](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Pharnext Reports First Half 2022 Financial Results
![SISM Investors stuft Condor Technologies NV mit Buy-Rating ein: https://mms.businesswire.com/media/20220822005263/en/1549500/5/6BB4D3E2-F9E8-4B4B-A919-BACC3F99E5C0_4_5005_c.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeFArV0E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2da7e5bf957891e25309b3dd67bbda1722bcb9e8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/6BB4D3E2-F9E8-4B4B-A919-BACC3F99E5C0_4_5005_c.jpg?locale=us)
SISM Investors stuft Condor Technologies NV mit Buy-Rating ein
Ernest C. Schlotter, Senior Analyst bei SISM Investors mit Sitz in Zürich, Schweiz, und laut StarMine, einem ehemals zu Thomson Reuters gehörenden Unternehmen, ein Vier-Sterne-Analyst
![SISM Investors Initiates Coverage on Condor Technologies NV With a Buy Rating: https://mms.businesswire.com/media/20220822005263/en/1549500/5/6BB4D3E2-F9E8-4B4B-A919-BACC3F99E5C0_4_5005_c.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeFArV0E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2da7e5bf957891e25309b3dd67bbda1722bcb9e8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/6BB4D3E2-F9E8-4B4B-A919-BACC3F99E5C0_4_5005_c.jpg?locale=us)
SISM Investors Initiates Coverage on Condor Technologies NV With a Buy Rating
Ernest C. Schlotter, a senior analyst at SISM Investors based in Zurich, Switzerland, and a four-star analyst according to StarMine, a former Thomson Reuters company, published an eight-page report
![BIOCORP und Merck KGaA, Darmstadt, Deutschland, schließen neue Partnerschaft für intelligente Arzneimittelverabreichung: https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNVAxRmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--27e0b79ca4263b2c37c92a647381d83a6cd1d5c8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Logo_Biocorp.jpg?locale=us)
BIOCORP und Merck KGaA, Darmstadt, Deutschland, schließen neue Partnerschaft für intelligente Arzneimittelverabreichung
BIOCORP (FR0012788065 – ALCOR / PEA/KMU-qualifiziert) (Paris:ALCOR), ein französisches Unternehmen, das auf die Konzeption, Entwicklung und Herstellung innovativer medizinischer Geräte